SymBio Pharmaceuticals Limited

Business Details

The sole segment of the SymBio Pharmaceuticals Group. Its two pillars are domestic sales of the flagship product Treakisym® (bendamustine hydrochloride hydrate) and global development of the antiviral drug BCV (Brincidofovir). Under a lab-less, fab-less strategy, the company suppresses fixed costs while concentrating management resources on the introduction and development of post-POC products. In the first quarter of FY2026 (ending December 2026), net sales were ¥233 million (down 11.6% year on year), and the operating loss widened to ¥2,341 million. Material uncertainty exists regarding the going-concern assumption.

Recent Overview

Development progress such as BCV Phase III FPI achievement and PML Phase III initiation, but losses more than doubled year on year due to a sharp increase in R&D expenses

In the first quarter of FY2026 (ending December 2026) (January to March), FPI was achieved (March 2026) in the global Phase III clinical trial of IV BCV targeting adenovirus infection after hematopoietic stem cell transplantation. An NIH-led Phase II clinical trial targeting PML was also initiated (February 2026). The intellectual property base was strengthened through the acquisition of use patents in the US (adenovirus infection) and Japan (malignant lymphoma). On the other hand, research and development expenses surged to ¥1,991 million (up 143.1% year on year), and the operating loss widened to ¥2,341 million (up 100.2% year on year). Equity capital fell to -¥72 million, resulting in negative net worth. Capital stock and capital surplus each increased by approximately ¥708 million due to the exercise of stock acquisition rights and conversion of convertible bonds, but this was insufficient to offset the widening losses.

Key Products

Growth Drivers

• Progress in the BCV global Phase III clinical trial (FPI achieved in March 2026, plan to enroll 180 patients at 80 sites, targeting EU marketing authorization application in the second half of 2028)
• Future partnering and business alliance revenue (incorporated into the full-year net sales forecast of ¥3,891 million for FY2026, ending December 2026)
• Multifaceted expansion of BCV indications (adenovirus infection, CMV infection, PML, malignant lymphoma, glioblastoma, head and neck cancer, EBV-associated gastric cancer, Alzheimer's-type dementia, multiple sclerosis)
• Advancement of joint development in the PML and multiple sclerosis fields through multiple CRADAs concluded with the NIH (the MS-related CRADA was extended by three years in March 2026)
• Early commercialization of the IVD business (ultra-sensitive immunoassay) and promotion of collaboration with external partners (joint patent with Nippon Steel Chemical & Material, PCT application filed)
• Expansion of the intellectual property portfolio through the acquisition of use patents in the US, Japan, and Europe
• Partial coverage of R&D expenses through grants awarded for orphan drug test and research subsidies
• Establishment of a flexible fundraising framework through the exercise of stock acquisition rights and conversion of convertible bonds

Risks

• Material uncertainty exists regarding the going-concern assumption (operating loss, ordinary loss, and net loss for four consecutive periods, with equity capital turning negative)
• Continued decline in Treakisym® sales (three generic companies have already entered the market, the impact of drug price revisions continues, Q1 net sales of ¥233 million, down 11.6% year on year)
• Widening losses due to a sharp increase in R&D expenses (Q1 R&D expenses of ¥1,991 million, up 143.1% year on year; full-year operating loss forecast of ¥4,231 million)
• Risk of failure or delay in the BCV global Phase III clinical trial (the EU marketing authorization application in the second half of 2028 is premised on trial success; a trial failure would have a major impact on business continuity)
• Risk that partnering and business alliance agreements may not materialize (the full-year forecast for FY2026, ending December 2026, includes a substantial amount of unconfirmed revenue)
• Risk of deterioration in the fundraising environment (cash balance of ¥1,897 million, negative net worth of -¥72 million, reliance on equity financing)
• Redemption risk related to convertible bond-type stock acquisition rights (¥700 million due within one year, with ¥100 million remaining in fixed liabilities)
• Risk of share dilution due to the exercise of stock acquisition rights (the number of shares issued increased from 59,567 thousand shares at the end of the previous period to 72,238 thousand shares)